Skip to main content
logo
Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (HKG:2315)
Hong Kong flag Hong Kong · Delayed Price · Currency is HKD
57.15
-1.85 (-3.14%)
Apr 17, 2026, 11:55 AM HKT

HKG:2315 Revenue

In the year 2025, Biocytogen Pharmaceuticals (Beijing) had annual revenue of 1.38B CNY with 40.63% growth. Biocytogen Pharmaceuticals (Beijing) had revenue of 437.93M in the quarter ending December 31, 2025, with 12.12% growth.

Revenue
1.38B CNY
Revenue Growth
+40.63%
P/S Ratio
29.61
Revenue / Employee
1.06M CNY
Employees
1,306
Market Cap
45.43B HKD

Revenue Chart

* This company reports financials in CNY.

Revenue History

Fiscal Year EndRevenueChangeGrowth
Dec 31, 20251.38B398.35M40.63%
Dec 31, 2024980.45M263.54M36.76%
Dec 31, 2023716.91M183.03M34.28%
Dec 31, 2022533.88M179.33M50.58%
Dec 31, 2021354.56M101.01M39.84%
Dec 31, 2020 Pro Pro Pro

Revenue Definition

Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.

Full Definition

Related Stocks

Company NameRevenue
Sino Biopharmaceutical35.43B
3SBio19.69B
Genscript Biotech7.47B
Shanghai Henlius Biotech7.42B
RemeGen3.62B
Shanghai Junshi Biosciences2.78B
InnoCare Pharma2.64B
Duality Biotherapeutics2.06B
Revenue Rankings

Biocytogen Pharmaceuticals (Beijing) News

More News